The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

Biotech picks highlight cystic fibrosis drug trials, rare-disease therapies and upcoming regulatory catalysts as clinical data and approvals approach.

A former executive at companies like Syndax Pharmaceuticals, AstraZeneca and Pfizer has landed a new funding round for his latest venture.

Despite world-class AI-biotech research, a Nobel Prize-winning protein design lab and proximity to global AI expertise, Washington's life sciences sector is still learning to tell its story.

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...